Hatim Husain

Hatim Husain contributed to KEYNOTE-407 establishing pembrolizumab plus chemotherapy for squamous NSCLC and has expertise in liquid biopsy and ctDNA monitoring in the context of first-line immunotherapy for lung cancer. His translational research explores ctDNA dynamics as biomarkers of IO response and resistance, and he leads early-phase trials of novel IO combinations. Husain has been active in developing next-generation sequencing and molecular profiling approaches for NSCLC immunotherapy selection. His work bridges genomics with clinical immunotherapy outcomes in thoracic cancers.